Ligand Pharmaceuticals Inc., of San Diego, said partner Pfizer Inc., of New York, reported that the European Medicines Agency accepted for review the marketing authorization application for bazedoxifene/conjugated estrogens (BZA/CE), under review for use in postmenopausal women with a uterus for treating estrogen deficiency symptoms and treating osteoporosis in women at risk of fracture

Anavex Life Sciences Corp., of Vancouver, British Columbia, reported a synergic effect between its Alzheimer's disease candidate Anavex 2-73 and the Alzheimer's treatments Aricept (donepezil, Pfizer Inc.) and Namenda (memantine, Forest Laboratories Inc

Verastem Inc., of Cambridge, Mass., said it in-licensed exclusive worldwide rights from New York-based Pfizer Inc

It partnered with Pfizer Inc., of New York, which acquired the rights through its February 2011 buyout of King Pharmaceuticals Inc., of Bristol, Tenn

Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said the FDA issued a complete response letter (CRL) on the new drug application for Eliquis (apixaban) for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation

Pfizer Inc., of New York, received FDA approval for the use of Lyrica (pregabalin) capsules CV in the management of neuropathic pain associated with spinal cord injury

Pfizer Inc., of New York, and Cold Spring Harbor Laboratory established a research collaboration to develop a human short hairpin RNA library to silence gene expression through the process of RNA interference and to identify new therapeutic targets in cancer

The consortium plans to develop an integrated platform to identify diverse small molecules active against drug targets using very large peptide libraries to explore chemical space...To date, the component technologies have been used individually in more 170 drug discovery projects

Protalix BioTherapeutics Inc., of Carmiel, Israel, received a $25 million milestone payment from New York-based Pfizer Inc

Part of its research activities are funded through a recent agreement with New York-based Pfizer Inc., and the firm said it aims to ink more agreements of that type

Part of its research activities are funded through a recent agreement with New York-based Pfizer Inc., and the firm said it aims to ink more agreements of that type. (See BioWorld Today, Feb. 15, 2012

Pfizer Inc., of New York, presented reports of studies on Lyrica (pregabalin) at the American Pain Society meeting in Honolulu, including an exploratory study, using functional magnetic resonance imaging (fMRI), showing that Lyrica decreased connectivity between various parts of the brain involved in pain processing in fibromyalgia patients

Pfizer Canada Inc., of Kirkland, Quebec, part of Pfizer Inc., launched Xyntha Solofuse in Canada to prevent and control hemorrhagic episodes in patients with hemophilia A. The preloaded device delivers Xyntha (recombinant Factor VIII) by intravenous infusion after reconstitution of a freeze-dried powder

Sagent Pharmaceuticals Inc., of Schaumburg, Ill., said it launched irinotecan injection, a generic form of Camptosar, New York-based Pfizer Inc.'s chemotherapy drug

Atorvastatin is a generic version of New York-based Pfizer Inc.'s top-selling cholesterol-lowering drug Lipitor

In other news, Gentium said it received the Day 180 list of outstanding issues from the European Committee for Medicinal Products for Human Use in connection with the marketing authorization application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy...The company said it plans to submit its responses within 60 days and, if no other issues are raised, it anticipates a drug approval as early as the

Silence Therapeutics plc, of London, said the amendment of an agreement by partner Quark Pharmaceuticals Inc., of Fremont, Calif., with Pfizer Inc., of New York, expanded its potential milestones

Antares Pharma Inc., of Ewing, N.J., said development partner Teva Pharmaceutical Industries Ltd., of Jerusalem, entered into a settlement agreement with Pfizer Inc

CrystalGenomics Inc., of Seoul, South Korea, reported results from a Phase IIb osteoarthritis trial of CG100649, its next-generation nonsteroidal anti-inflammatory drug candidate, showing that the trial met its primary and secondary endpoints evaluating the safety, analgesic efficacy and functional benefits of CG100649 vs. Celebrex (celecoxib, Pfizer Inc.) over a four-week treatment period in subjects recording moderate to severe hip or knee osteoarthritis pain